[Testing of the clinical effects of a cavain-magnesium-orotate combination in inmates of a nursing home using a double-blind study].
D000367:Age Factors; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005859:Germany, East; D006707:Homes for the Aged; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009963:Orotic Acid / Q000627:therapeutic use*; D011714:Pyrans / Q000627:therapeutic use*; D011753:Pyrones; D012824:Silicic Acid / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014653:Vascular Headaches / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy
D004338:Drug Combinations; D007783:Lactones; D011714:Pyrans; D011753:Pyrones; D012824:Silicic Acid; D009963:Orotic Acid; D008274:Magnesium; C011889:kavain
Uberprüfung der klinischen Wirksamkeit einer Kavain-Magnesium-Orotat-Kombination an Heimbewohnern eines Krankenpflegeheimes in einer doppelten Blindstudie